On November 1, 2024, Knowledge Ecology International (KEI) submitted a proposal for the addition of risdiplam to the World Health Organization’s (WHO) Model List of Essential Medicine (EML). You can access the full proposal here: risdiplam2WHOEML1Nov2024 The EML, updated every… Continue Reading
On October 1, 2021, the WHO published the new edition of its Model Lists (the EML) of Essential Medicines and Essential Medicines for Children. WHO Documents Press Release Executive Summary World Health Organization model list of essential medicines: 22nd list… Continue Reading
KEI submissions to the WHO Model List of Essential Medicines (EML) 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network:… Continue Reading
On Monday, 1 April 2019, Knowledge Ecology International (KEI) delivered the following oral statement to the Open Session of the 22nd Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. The program for the open… Continue Reading
The WHO Essential Medicines List is a major WHO tool used to expand access to medicines. In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list. The WHO is currently in… Continue Reading
On 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network: YP-CDN submitted a Proposal for the Inclusion of Trastuzumab in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Breast Cancer to WHO’s Exper Continue Reading
At the opening of the 67th World Health Assembly, today the Young Professionals Chronic Disease Network (YP-CDN), Knowledge Ecology International (KEI), and Universities Allied for Essential Medicines (UAEM) released a briefing, “Cancer medicines are essential in reducing the global burden of non-communicable diseases.”
KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,
A full copy of the paper is available in PDF format here.
The following is from the introduction (sans footnotes, which are in the PDF version):
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading